Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Research Grade Lintuzumab
Overview
Catalog No.
HB185026
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Purity
>95% purity as determined by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Purification
Protein A/G purified from cell culture supernatant.
Endotoxin level
Please contact the lab for this information.
Expression system
Mammalian Cells
Accession
P20138
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternative name
225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, 166089-32-3
Note
For research use only. Not suitable for clinical or therapeutic use.
Description
Images
Bioactivity
Detects CD33 in indirect ELISAs.
SDS-PAGE
SDS-PAGE for Research Grade Lintuzumab.